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1. Introduction 
Chronic lymphocytic leukemia (CLL) is characterised by the accumulation of mature 
CD5/CD19 B-lymphocytes in the blood, bone marrow, lymph nodes and spleen 
(Caligaris-Cappio & Hamblin, 1999). Although the role of cellular proliferation disorders in 
CLL may originally have been underestimated, the typical characteristic of the disease is still 
regarded as a failure of malignant cells to undergo apoptosis (Munk Pedersen & Reed, 
2004). CLL is a heterogeneous disease and although it is relatively stable in some patients, it 
progresses rapidly in others (Caligaris-Cappio & Hamblin, 1999). The mutational status of 
immunoglobulin heavy chain variable gene segment (IGHV) and the expression of CD38 
and/or ZAP70 are important prognostic factors of disease so their detection is very useful 
for stratification of patients into indolent or aggressive subgroups (Hamblin et al., 1999; 
Krober et al., 2002; Orchard et al., 2004).  
However, a more robust approach to subclassifying CLL is to identify the genomic changes 
in the malignant clone. The heterogeneity of the disease may result from different genetic 
abnormalities in distinct subclasses of patients. Furthermore, there is a strong relationship 
between specific genetic aberrations and the clinical course of the disease. On the basis of 
the mutational status of the variable region of the IGH, CLL can be divided into two 
subtypes. Somatic hypermutation of IGHV occurs in more than half of the patients and is 
associated with a more indolent clinical course. Additionally, deletions of the long arm of 
chromosome 13 or 11 and the short arm of chromosome 17, as well as trisomy of 
chromosome 12, are prognostically most important for the CLL patients. The most common 
abnormality in CLL, observed in more than 50% patients, is del(13)(q14) and, along with 
hypermutation of IGHV, this is linked with a good prognosis (Damle et al., 1999; Schroeder 
& Dighiero, 1994). 
2. Gene expression profiling 
Recent advances in genomics have transformed research on hematologic malignancies by 
improving molecular approaches to gene networks. New technologies have been designed 
to meet the need for methods to address the functional significances of nucleotides 
sequences. Microarrays have emerged as powerful tools for increasing the potential of 
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standard methods through genome-wide biological studies. They have been focused mainly 
on gene expression profiling (GEP), but also on mutational screening, genotyping of 
polymorphisms and copy number analyses. 
2.1 Contribution of microarray study to comprehension of CLL pathophysiology 
DNA microarrays can be used to detect either DNA, as in comparative genomic 
hybridization, or to detect RNA, usually as complementary DNA (cDNA) after reverse 
transcription. The process of measuring gene expression via cDNA is called expression 
analysis or expression profiling (Schena et al., 1995). Alizadeh et al., (2000) investigated the 
construction of a commercial cDNA microarray (Lymphochip) for studies of normal and 
malignant human cells. They examined each stage of lymphocyte differentiation that can 
be defined by a characteristic gene expression signature. Genes that are coregulated by 
over hundreds of experimental conditions often encode functionally related proteins. 
GEP also provide an unprecedented ability to define the molecular and functional 
relationships between normal and malignant lymphocyte cell populations (Alizadeh & 
Staudt, 2000).  
Using different microarray platforms such as oligonucleotide arrays, cDNA arrays printed 
on glass slides and on nylon membranes, Wang et al., (2004) found that several genes were 
consistently differently expressed between CLL and normal B-cell samples. The following 10 
genes were shown to be expressed differently in CLL compared with tonsillar B-
lymphocytes and plasma cells: FCER2 (CD23), FGR, TNFRSF1B, CCR7, IL4R, PTPN12, 
FMOD, TMEM1, CHS1 and ZNF266 (Zent et al., 2003). 
The results of GEP tests on CLL cells indicated that their profile was more closely related to 
non-proliferating B cells, or memory B cells, than to cells from a naïve germinal centre (GC), 
mitogenically activated blood cells or CD5+ B cells (Klein et al., 2001). Over the last few 
years, global GEP has been revised and defined CLL as a tumor of antigen-experienced B 
cells. These could be marginal zone or memory B cells. Now we know, that CLL results not 
only from an accumulation of transformed B cells, due to an imbalance between cell 
generation and cell death rate, but also from a proliferation of B cells in particular 
microenvironments in the lymphoid tissues and bone marrow (Klein & Dalla-Favera, 2010). 
Based on these findings, it can be suggest, that the leukemic B cells are more complex 
mixture than we have hitherto expected. Other genes have been dubbed CLL signature genes 
because they are selectively expressed in CLL and not in normal cells or other types of B-cell 
malignancy (Rosenwald et al., 2001). The CLL signature includes genes already known to be 
characteristic for CLL, such as CD5, IL2Rα (CD25) and BCL2, and genes not previously 
known to be expressed in CLL, such as WNT3, TITIN, ROR1 and MRC-OX2. ROR1 and 
MRC-OX2 encode membrane proteins, so they might be useful for decisions concerning 
treatment with humanised monoclonal antibodies. WNT3 probably regulates B lymphocyte 
proliferation (Zent et al., 2003; Reya et al., 2000). A study by Zent et al., (2003) showed that 
the GEP of CLL lymphocyte is different from multiple myeloma (MM) cells. CLL expressed 
higher levels of tumour necrosis factor (TNF) and TNF receptor pathway genes (LTB, 
TRAF5, TNFRSF9, TNFSF7 and LITAF). The IAP family gene (BIRC1) and the XIAP 
antagonist (HSXIAPAF1) were expressed at higher levels only in CLL to MM, similar to 
BCL-2 expression.  
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2.2 Contribution to the identification of new genes that might be considered as 
prognostic factors 
In the last few years, the development of cytogenetics and molecular biology has led to the 
release of new genetic prognostic markers such as IGHV mutational status, genomic 
aberrations and individual gene mutations.  
To determine possible genetic and molecular abnormalities related to early clinical 
progression in CLL, Fernandez et al., (2008) investigated alterations in genomic and gene 
expression profiles in a series of samples sequentially obtained at diagnosis in early stage of 
the disease and at the time of clinical progression before treatment. A group of 58 genes was 
identified by supervised analysis comparing the initial and progressed samples: 37 were 
over-expressed while 21 were down-regulated. No significant differences were observed in 
the expression of these genes in samples from the three CLL cases with stable clinical 
decease. Functional analysis of the over-expressed genes showed that they are involved in 
different pathways, including cell cycle and cell growth (MCM4, RAPGEF2, OGG1, ESCO1, 
ESR1, ACTL6A, CENPJ, ATG5) and ion regulation (MYLC2PL, ADRB1, TRPV5, TMCO3). 
Interestingly, 6 of the 21 down-regulated genes were considered negative regulators of 
integrin-mediated cell adhesion and motility (PRAM1, CDC42EP4, COL4A2, PLCB2, 
RAPGEF1, FLNA). These findings suggest that in early stage CLL, clinical progression is 
associated with inactivation of tumour suppressor genes and modulation of the expression 
of a small number of genes that are inhibitors of cell adhesion and motility. 
Ferrer et al., (2004) performed gene expression profiling on 31 CLL cases and investigated 
the HV gene mutation status by nucleotide sequencing. The array data showed that the 
greatest differences between the unmutated (20 cases) and the mutated (11 cases) groups 
were observed in the expression of such genes as: ZAP70, RAF1, PAX5, TCF1, CD44, SF1, 
S100A12, NUP214, DAF, GLVR1, MKK6, AF4, CX3CR1, NAFTC1 and HEX. ZAP70 was 
significantly more highly expressed in the IGHV-unmutated CLL group, whereas all the 
other genes were more highly expressed in the IGHV-mutated cases. This study confirmed 
that ZAP70 expression can predict the HV mutation status and suggested that RAF1, PAX5 
and other differentially expressed genes may be good markers for differentiating between 
these two groups and can serve as prognostic markers. 
2.2.1 Deregulated apoptosis in poor-prognosis CLL 
CLL is a heterogeneous disease with marked variability in its clinical course. With the aim of 
identifying genes potentially related to disease progression, Fält et al., (2005) performed 
gene expression profiling on CLL patients with non-aggressive disease or with progressive 
disease requiring therapy. The Affymetrix GeneChip U95Av2 technique was used in 11 
samples obtained from CLL patients with stable and 10 patients with clinically progressive 
disease. To discriminate samples from progressive and stable disease, a group of genes was 
chosen as markers; two genes in particular, PPP2R5C and RBL2, were included among the 
best discriminators as both were expressed at lower levels in progressive than in stable CLL. 
These genes are known to be key regulators of both the cell cycle and the 
mitochondria/cytochrome c apoptotic pathway. This procedure allowed samples with 
progressive and stable disease to be identified with 70-90% accuracy. 
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Stratowa et al., (2001) studied 54 peripheral blood lymphocyte samples obtained from 
patients with CLL to determine the expression levels of 1024 genes on a cDNA microarray 
and to correlate them with patient survival. Overall survival (OS) of CLL patients displaying 
low expression of genes coding for IL-1, IL-8 and L-selectin was shorter than for patients 
with high expression of these genes. However, high expression of TCL1 was connected with 
decreased patient survival. These findings suggest that CLL prognosis may be connected 
with a defect in lymphocyte trafficking, causing accumulation of leukemic B cells in the 
blood. 
Edelmann et al., (2008) used a microarray-based GEP (Affymetrix U95A) to study how the 
stroma modulates the survival of CLL cells in in vitro co-culture model employing the 
murine fibroblast cell line M2-10B4. CLL cells cultured in direct contact with the stromal 
layer (STR) showed significantly better survival than cells cultured in transwell (TW) inserts 
above the M2-10B4 cells. STR induced a more marked up-regulation of the PI3K/NF-
B/Akt signaling pathway genes (INPP4A, NFKB2, REL and MAPKAPK2) than TW 
conditions and mediated a pro-angiogenetic switch in the CLL cells by up-regulating VEGF 
and OPN and down-regulating the anti-angiogenetic molecule TSP-1. The findings also 
suggest that TSP-1 expression in CLL cells may be related to both disease stage and CLL 
subtype as defined by ZAP70 and CD38 expression. OPN protein secretion may be 
correlated to disease progression in CLL.  
GEP used to predict the prognosis in CLL is presented in Table 1 and Table 2. 
2.3 Contribution of GEP microarray study to pharmacogenomics 
Drug resistance remains a major problem of CLL treatment. Owing to their high 
adaptability to therapeutic conditions, malignant tumour cells frequently develop escape 
mechanisms in response to cytostatic drugs. It is very difficult to predict a tumour’s reaction 
to drugs because it can deploy multiple cellular mechanisms such as enhanced DNA repair, 
elevated levels of drug transporters, over-expression of detoxifying enzymes or apoptosis 
inhibition, which are often involved in the development of drug resistance. To monitor the 
multiple alterations by which CLL may become drug-insensitive, highly parallel analyses 
such as the DNA microarray technique are required. This technique affords new ways of 
predicting resistance and sensitivity to therapy (Dietel & Sers, 2006). 
2.3.1 In vitro experiments 
There is now well documented that some genes induce apoptosis, whereas the others can 
inhibit this phenomenon (Table 3). It is also known that drugs used for therapy regimens 
can change GEP and modify apoptosis. However, the knowledge concerning the drug 
influence on GEP is still insufficient and demands further studies. 
The study by Vallat et al., (2003) combined two series of microarray analyses (Hu-FL 
GeneChips, Affymetrix, 7,070 genes) with four sensitive and three resistant CLL samples 
and compared their gene expression patterns before and after in vitro irradiation-induced 
apoptosis. Sixteen differentially expressed genes (2-fold, specifically in resistant cells) were 
disclosed by data analysis. After the validation of the selected genes by quantitative RT-PCR 
on seven microarray samples, their altered expression level was confirmed on a further 15 
CLL samples not previously included in the microarray analysis. Eleven patients with 
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Alterations in gene 
expression 
Gene description 
Cell cycle and transcription genes 
RAF1  V-raf-1 murine leukemia viral oncogene homolog 1 
PAX5  Paired box gene 5 
TCF1  Transcription factor 1 
CD44  CD44 antigen 
SF1 (ZNF162)  Splicing factor 1 (zinc finger protein 162) 
S100A12  S100 calcium binding protein A12 
NUP214  Nucleoporin 214 kD 
DAF  CD55 molecule, decay accelerating factor for complement 
GLVR1  Solute carrier family 20 (phosphate transporter) member 1 
(Glv-r) 
MKK6  Mitogen-activated protein kinase kinase 6 (MKK6, MAPKK6, 
MEK6) 
AF4  Pre-B-cell monocytic leukemia partner 1; (AF4, AFF1, MLLT2) 
CX3CR1  Chemokine (C-X3-C motif) receptor 1 (CCRL1, GPR13) 
NAF  T cell chemotactic factor (NAF, IL-8) 
HEX  Hematopoietically expressed homeobox (HEX, HHEX) 
Cell cycle and cell growth 
MCM4  Minichromosome maintenance complex component 4 
RAPGEF2  Rap guanine nucleotide exchange factor (GEF) 2 (RAPGEF2) 
OGG1  8-oxoguanine DNA glycosylase (OGG1, HMMH, HOGG1) 
ESCO1  Establishment of cohesion 1 homolog 1 (ESCO1, CTF, ECO1) 
ESR1  Estrogen receptor 1 (ESR1, ER ) 
ACTL6A  Actin-like 6A (ACTL6A, Arp4, BAF53A, INO80K, MGC5382) 
CENPJ  Centromere protein J (CENPJ, BM032, CPAP, LAP, LIP1) 
ATG5  ATG5 autophagy related 5 homolog (APG5-LIKE, APG5L, 
ASP) 
Ions regulation 
MYLC2PL  Myosin, light chain 10, regulatory (MYL10, MYLC2PL, PLRLC) 
ADRB1  Adrenergic, beta-1-, receptor (ADRB1, B1AR, BETA1AR, RHR) 
TRPV5  Transient receptor potential cation channel, subfamily V, 
member 5 
TMCO3  Transmembrane and coiled-coil domains 3 (TMCO3, C13orf11) 
Cell signalling 
INPP4A  Inositol polyphosphate-4-phosphatase, type I (TVAS1, 
INPP4A) 
NFKβ2  Nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2 
REL  V-rel reticuloendotheliosis viral oncogene homolog 
MAPKAPK2  Mitogen-activated protein kinase-activated protein kinase 2 
(MK2) 
Gene expression: upregulation   
Table 1. GEP in CLL, which may predict a good prognosis. (Edelmann et al., 2008; Fält et al., 
2005; Fernandez et al., 2008; Ferrer et al., 2004; Stratowa et al., 2001) 
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Alterations in gene 
expression 
Gene description 
Cell adhesion and motility 
RAPGEF1  Rap guanine nucleotide exchange factor (GEF) 2 
FLNA  Alpha-filamin; endothelial actin-binding protein  
PRAM1  PML-RARA regulated adaptor molecule 1  
CDC42EP4  CDC42 effector protein (Rho GTPase binding) 4  
COL4A2  Collagen alpha-2(IV) chain  
PLCB2  Phospholipase C, beta 2  
IL1β  Interleukin 1 beta 
IL-8  Interleukin 8 (T cell chemotactic factor) 
L-selectin  Leukocyte-endothelial cell adhesion molecule 1 
(LECAM-1) 
Cell cycle and signal transduction 
PPP2R5C   Protein phosphatase 2, regulatory subunit B', gamma  
RBL2  Retinoblastoma-like 2 (p130)  
Cell growth 
TSP-1  Thrombospondin-1  
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Cell adhesion and motility 
TCL-1  T-cell leukemia/lymphoma 1A  
Cell cycle and signal transduction 
VH 3.21  Immunoglobulin heavy variable 3-21 
ZAP70  Tyrosine-protein kinase ZAP-70 
Cell growth 
OPN  Osteopontin  
VEGF  Vascular Endothelial Growth Factor  
Gene expression: up  - and downregulation   
Table 2. GEP in CLL, which may predict the poor prognosis. (Edelmann et al., 2008; Fält et 
al., 2005; Stratowa et al., 2001; Thorselius et al., 2006) 
malignant B cells that were sensitive to in vitro radiation-induced apoptosis had never been 
treated, whereas eight of the 11 patients with resistant disease had previously been treated 
with fludarabine (FA), cyclophosphamide (C) or chlorambucil (CHB). In the 11 sensitive and 
11 resistant CLL samples tested, genes were found to be specific for all the resistant samples; 
TR3, HLA-DQA1, MTMR6, C-MYC, C-REL, C-IAP1, MAT2A and FMOD were up-regulated, 
whereas MIP1A/GOS19-1 homolog, STAT1, BLK, HSP27 and ECH1 were down-regulated. 
The result of this study was defining clinically relevant new molecular markers specific to 
resistant CLL subtypes. 
Morales et al., (2005) investigated the regulation of apoptosis in B-CLL cells using cDNA 
microarrays (Human Apoptosis GEArray Q Series, Superarray) with 96 known genes. Data 
were obtained from and compared between two groups of CLL patients with either non-
progressive, non-aggressive, previously untreated disease in which the leukemic cells were 
sensitive to in vitro FA-induced apoptosis, referred to as sensitive B-CLL (sB-CLL), or 
progressive, chemotherapy-refractory disease in which the leukemic cells were resistant to 
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in vitro FA-induced apoptosis, referred to as resistant B-CLL (rB-CLL). By performing a 
supervised clustering of genes that most clearly discriminated rB-CLL from sB-CLL, a small 
group of genes was identified. BFL1 was the most strongly discriminating gene, with higher 
expression in rB-CLL. This finding suggests that BFL1 may be an important regulator of CLL 
apoptosis, which could contribute to disease progression and resistance to chemotherapy, 
and could be a potential future therapeutic target.     
Direct physical interaction of stromal cells with CLL cells and overexpression of RAD51 and 
LIG4 (DNA ligase IV) in the leukemic cells have been found. These genes code for DNA 
repair enzymes in mammalian cells (Edelmann et al., 2008). Given that RAD51 expression in 
CLL was previously reported to correlate with resistance to CHB. These findings may 
provide a molecular-level explanation of the capacity of stromal cells to protect CLL cells 
from drug-induced apoptosis (Christodoulopoulos et al., 1999). 
Segel et al., (2003) have used a cDNA microarray containing approximately 40,000 human 
gene sequences to obtain GEP for untreated and tetradecanoyl phorbol acetate (TPA)-treated 
B-CLL cells. Three genes, EGR1, DUSP2 and CD69, showed a 2-fold or greater increase in 
mRNA transcription in two studies. Several genes (PKC, N-MYC, JUN D and BCL2), 
previously reported to be overexpressed in CLL lymphocytes, were also overexpressed in 
these studies but were not altered by TPA treatment. These findings suggest that the products 
of these three genes may be central to early steps in the TPA-induced evolution of B-CLL cells 
to a plasma-cell phenotype. A variety of stimulators such as TPA, bryostatin, IL-2 and others 
can induce CLL lymphocytes to mature in vitro to an immunoglobulin-producing and -
secreting phenotype. Such treatment corrects some metabolic defects such as impairment of 
the L-system amino acid transport, but not others such as diminished membrane gamma-
glutamyl transpeptidase (GGTP) activity. 
GEP allows the study of a large number of genes and analysis of global pathways rather 
than single targets. Stamatopoulos et al., (2009) revealed the influence of valproic acid (VPA) 
on molecular changes in two key pathways in cancer: apoptosis and proliferation. The study 
was conducted on purified B cells obtained from 14 CLL patients. Microarray analysis was 
performed with an Affymetrix GeneChip Human Genome U133 Plus 2.0 array. Several 
genes (i.e. CD5, BCL2, CD23, LCK, PIM1) described as overexpressed in CLL by Wang et al., 
(2004) were downregulated by VPA in this study, whereas genes described by Wang et al., 
(2004) as underexpressed in CLL (i.e. BCLA1, C-MYC, DUSP2 and PEA15) were upregulated 
by VPA. The authors suppose that these results indicate that VPA could restore a more 
‘normal’ epigenetic code and, in this way, could allow normal cellular processes that were 
silenced after malignant transformation. No differences among the GEP of ZAP+ and ZAP− 
patients (poor and good prognosis, respectively) were found, indicating that VPA was 
acting independently of disease aggressiveness. It had also been observed that VPA acted on 
an important number of genes involved in apoptosis: BCL2, XIAP, FLIP, BCL-xL, AVEN and 
cIAP, which as a result, were significantly downregulated, whereas CASP 2, 3, 6, 8, 9, and 
BAX, BAK, APAF1 and P53 were all significantly upregulated. The ratio of anti- and 
proapoptotic genes determines the tendency towards cell death or cell survival. Moreover, a 
large number of cell-cycle genes were upregulated, not only CDK1, 2, 4, and 6, cyclin B1, B2, 
D1, D2, E1 and E2, but also inhibitors of cell cycle, such as P15, 16, 18, 19 and 21. The 
deregulated and simultaneous expression of all these genes is probably one of the reasons 
for proliferation inhibition (Stamatopoulos et al., 2009).   
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In our department, we identified differentially expressed genes in lymphocytes obtained from 
CLL patients and incubated with FA or cladribine (2-chlorodeoxyadenosine; 2-CdA) (Table 4). 
Among 93 studied apoptotic genes by means of 384 TaqMan Low Density Array (Applied 
Biosystems) most of them were downregulated, whereas such a few of them were 
upregulated: BAD, TNFRSF21, DAPK1 – in 2-CdA cultured group and CARD6 and CARD9 in 
FA cultured group. We have also noticed 4 genes (BAK1, BAX, FAS and PUMA) with about a 
20- or more –fold decrease in gene expression with respect to control samples. Interestingly, in 
the above-mentioned genes we have found great differences in fold change value between FA 
and 2-CdA. The expression of two of them, BAX and PUMA, were considerably decreased 
when lymphocytes were incubated with FA. It may be hypothesized that the high ratio 
between anti- and proapoptotic gene expression might account for the failure to achieve 
complete response after purine nucleoside analogues (PNAs) therapy. Additionally, 2-CdA 
has inhibited to a lower extent the expression of PUMA and BID as compared to FA (Franiak-
Pietryga I, Korycka-Wolowiec A, unpublished data), which might confirm the results reported 
by Robak et al., (2009) that 2-CdA, but not FA, is the most effective drug against P53-defective 
cells. At this stage of our knowledge, probably it is too far-fetched to make a suggestion that 
FA mostly triggers apoptosis in intrinsic pathways to caspase activation, while 2-CdA induces 
apoptosis via death receptor activation (extrinsic pathway) and by stress-inducing stimuli 
(intrinsic pathway). To confirm this hypothesis, further experiments are to be conducted in our 
department. Besides the in vitro experiments also in vivo studies play an important role in the 
increase of our knowledge on gene expression profiling. 
2.3.2 In vivo studies 
The study of CLL by Plate et al., (2000) was directed at understanding the signals that maintain 
viability in vivo and are lost when the leukemic cells are removed from the body, such that 
they immediately begin to undergo apoptosis ex vivo. Differences in gene expression between 
freshly isolated B-CLL cells and those maintained in vitro with and without FA were measured 
using the ATLAS apoptosis cDNA microarray (Clontech, Palo Alto, CA). Many genes, 
especially cyclin D1, were under-expressed after culturing. The anti-apoptotic genes BAG1 and 
AKT2 were over-expressed. The greatest positive effect of FA was the up-regulation of JNK1.  
Rosenwald et al., (2004) profiled gene expression in CLL leukemic samples obtained before 
and during FA administration using Lymphochip DNA arrays prepared from 17,856 cDNA 
clones. The procedure selected 27 microarray elements, 18 of which represented named genes 
while the other 9 represented novel genes of unknown function. In seven CLL samples, a 
consistent gene expression (GE) signature of in vivo FA exposure was identified. Many of the 
FA signature genes were known P53 target genes and genes involved in DNA repair (P21, 
MDM2, DDB2, TNFRSF10B, PCNA and PPMID). Because in vivo treatment with FA induces a 
P53-dependent GE response, it has the potential to select P53 mutant CLL cells, which are 
more drug-resistant and are associated with an aggressive clinical course. Therefore, treatment 
of CLL patients with FA has the potential to select for outgrowth of P53 mutant subclones that 
would be cross-resistant to several other chemotherapeutic agents. Moreover, the gene 
expression response to  radiation was highly similar to the response to FA. 
The purine metabolism of B-CLL lymphocytes was studied by Marinello et al., (2006). Gene 
expression analysis was performed on samples obtained from 2 B-CLL patients. Data analysis 
revealed 17 genes whose expression varied at least 2-fold. Some purine metabolism genes 
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expressed differently from controls were identified. Among the de novo enzymes, the Gars-
Airs-Gart complex was over-expressed and IMPDH1 and APRT seemed under-expressed. An 
imbalance in the expression of the adenosine-related protein gene was also observed, with 
over-expression of CD26, CD38 and mtAK3, while ADORA 1 and cAK1 were under-expressed 
(Table 5). Simultaneous gene profiling of apoptosis-related factors and purine metabolism 
enzymes is of particular interest for drugs such as FA and 2-CdA, which are commonly used 
in CLL treatment. Three years later the above-mentioned data was confirmed on samples 
obtained from 5 B-CLL patients on a chip prepared with 57 genes. To the group of genes 
described previously some of new ones were added, including apoptosis-related proteins. 
CASP6, CASP8 and BCL2L1 (BCL-xL) were under-expressed, whereas IL-4, IL-18 were over-
expressed. In contrast, less significant changes were observed in the expression of some other 
anti- or proapoptotic factors like BAX and BCL10, respectively.  
To identify novel genes involved in the molecular pathogenesis of CLL, Proto-Siqueira et al., 
(2008) performed a serial analysis of gene expression (SAGE) in CLL cells and compared it 
with healthy B cells (nCD19). A gene ontology analysis revealed that TOSO, which plays a 
functional role upstream of the FAS extrinsic apoptosis pathway, was over-expressed in 
CLL cells. A positive correlation was observed between TOSO and BCL2, but not between 
TOSO and FLIP. The over-expression of TOSO and BCL2 might be responsible for BAX 
inhibition, which leads to the suppression of apoptosis and might be associated with poor 
prognosis in CLL. It is also known that bortezomib blocks BAX degradation in malignant B 
cells. TOSO might therefore be considered a possible target for small molecule therapy in 
combination with newer pro-apoptotic drugs such as bortezomib and lumiliximab. 
Giannopoulos et al., (2009) provided novel biological insights into the molecular effects of 
thalidomide and suggested the existence of a signature predictive of thalidomide response 
in CLL. GEP data on day 0 and 7, based on a paired supervised analysis, revealed a 
thalidomide-induced signature comprising 123 differentially expressed genes. Upon 
thalidomide monotherapy, an upregulation of genes, known to be involved in mediating 
thalidomide response, was observed. Such genes as FAS and CDKN1A, as well as novel 
candidate genes, such as STAT1 and IKZF1 were reported. Gene expression differences in 
responders as compared to nonresponders after thalidomide monotherapy on day 7 were 
determined. Responders showed lower expression of gene coding pro-survival cytokine 
such as IL-8 and lower level of TGFB1, whereas genes involved in apoptosis, i.e. CASP1, 
were more highly expressed than in nonresponders. Higher expression of ZAP70, as well as 
anti-apoptotic genes such as TRAF1, and genes involved in angiogenesis, (eg. ECGF1) was 
observed in nonresponders group. Thalidomide responders showed also lower JUN and 
CASP9 expression levels associated with deregulated insulin and RAS signalling pathways. 
In CLL being induced by NFKB activation, IL-8 may function as an autocrine growth and 
apoptosis resistance factor promoting cell survival. 
Our data depicts changes in apoptotic GEP in CLL patients treated with cladribine, 
cyclophosphamide and rituximab (CCR). The measurements were conducted by means of 
384 TaqMan Low Density Arrays (Applied Biosystems). Data analysis pointed 20 out of 93 
examined apoptotic genes, whose expression has significantly changed. Changes in GEP are 
mostly related to the intrinsic apoptotic pathway. The most significant differences in gene 
expression before, as opposed to after, treatment are demonstrated by antiapoptotic genes 
such as BCL2, BCL2L1, BIRC1, BIRC5 and BIRC8, whose expression is considerably 
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 decreased. Of the proapoptotic genes, NOXA, CASP10, ESRRBL1 and NFKBIZ are 
particularly distinguished, because they are significantly overexpressed (Table 4). 
Additionally, genes specifically clustered in terms of GEP, which was different in particular 
genes depending IGHV mutational status (Franiak-Pietryga et al., 2010). 
 
 
Gene 
expression 
Gene description 
Response to drugs 
and other chemical 
substances 
G
e
n
e
s 
o
v
e
re
x
p
re
ss
e
d
 
BAG1 BCL2-associated athanogene Positive effect to FA 
AKT2 Protein kinase Akt-2; promoter of cell survival Positive effect to FA 
BCL2 B cell lymphoma 2 associated oncogene Positive effect to TPA 
JNK1  
Mitogen-activated protein kinase 8; stress-
activated protein kinase; MAPK8 
Positive effect to FA 
TR3 
TR3 orphan receptor; early response protein 
NAK1 
Resistance to FA, C, 
CHB 
MTMR6 Myotubularin related protein 6 
Resistance to FA, C, 
CHB 
C-MYC Transcription factor, puf, and kinase 
Resistance to FA, C, 
CHB; Positive effect 
to VPA 
C-REL Proto-oncogene c-Rel 
Resistance to FA, C, 
CHB 
C-IAP1 Apoptosis inhibitor 1; BIRC2 
Resistance to FA, C, 
CHB 
N-MYC V-myc myelocytomatosis viral related oncogene Positive effect to TPA 
JUND Transcription factor jun-D Positive effect to TPA 
P21 Cyclin-dependent kinase inhibitor 1A, CDKN1A 
FA signature genes 
involved in DNA 
repair 
MDM2 P53 binding protein homolog 
FA signature genes 
involved in DNA 
repair 
TNFRSF10B 
Tumor necrosis factor receptor superfamily, 
member 10b, apoptosis inducing protein 
FA signature genes 
involved in DNA 
repair 
BFL1  BCL2-related protein A1, BCL2A1 
Resistance to F, 
Positive effect to VPA 
BAX  
BCL2 associated protein, apoptotic death-initiating 
protein 
FA, 2-CdA 
BCL10 CARD-containing apoptotic signaling protein FA, 2-CdA 
TOSO Fas apoptotic inhibitory molecule 3; FAIM3 
Bortezomib, 
Lumiliximab 
DUSP2 Dual specificity phosphatase 2 
Positive effect to TPA, 
VPA 
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FAS TNF receptor superfamily, member 6; TNFRSF6 
Positive effect to 
Thalidomide 
Resistance to FA, C, CHB 
CASP6 Caspase 6, enzyme of apoptotic pathway FA, 2-CdA 
CASP8 Caspase 8, enzyme of apoptotic pathway FA, 2-CdA 
BAX 
BCL2 associated protein, apoptotic death-initiating 
protein 
Bortezomib, 
Lumiliximab 
BCL-xL Anti-apoptotic BCL2-like 1; BCL2L1 Positive effect to FA 
BCL2 B cell lymphoma 2 associated oncogene Positive effect to TPA 
C – cyclophosphamide, 2-CdA – cladribine, CHB – chlorambucil, FA – fludarabine,  
TPA – tetradecanoyl phorbol acetate, VPA – valproic acid 
Table 3. Expression of apoptotic genes under the influence of drugs and other chemical 
substances. (Giannopoulos et al., 2009; Marinello et al., 2006; Morales et al., 2005; Plate et al., 
2000; Proto-Siqueira et al., 2008; Rosenwald et al., 2004; Segel et al., 2003; Stamatopoulos et 
al., 2009; Vallat et al., 2003).  
 
 
Gen 
expression 
Gen description 
Response to 
drug 
P
ro
a
p
o
p
to
ti
c 
g
e
n
e
s 
BAD  BCL2-associated agonist of cell death 2-CdA 
TNFRSF21  Tumor necrosis factor receptor superfamily, member 21 2-CdA 
DAPK1  Death associated protein kinase 1 2-CdA 
CARD6  Caspase recruitment domain family member 6 FA 
CARD9  Caspase recruitment domain family member 9 FA 
BAK1  BCL2-antagonist/killer1; BAK1 2-CdA, FA 
BAX  BCL2-associated X protein, isoform delta 2-CdA, FA 
PUMA  BCL2 binding component 3; p53 up-regulated modulator of    apoptosis; BBC3 2-CdA, FA 
FAS  TNF receptor superfamily, member 6; TNFRSF6 2-CdA, FA, CCR 
NOXA  Phorbol-12-myristate-13-acetate-induced protein 1; 
PMAIP1 
CCR 
CASP10  Caspase 10, apoptosis-related cysteine peptidase CCR 
ESRRBL1  Intraflagellar transport 57 homolog-IFT57; HIP1 CCR 
NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta; IKBZ CCR 
A
n
ti
a
p
o
p
to
ti
c 
g
e
n
e
s 
BCL2  B-cell leukemia/lymphoma 2 CCR 
BCL2L1  BCL2 like isoform 1 CCR 
BIRC1  Baculoviral IAP repeat-containing 1 CCR 
BIRC5  Baculoviral IAP repeat-containing 5 CCR 
BIRC8  Baculoviral IAP repeat-containing 8 CCR 
Gene expression:  up  - and downregulation  
2-CdA – cladribine, CCR – cladribine, cyclophosphamide and rituximab; FA – fludarabine  
Table 4. Genes involved in apoptosis (Franiak-Pietryga et al., 2010; Franiak-Pietryga I, 
Korycka-Wolowiec A, unpublished data) 
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GEP may have a predictive value for the effectiveness of anti-cancer therapy. Although 
numerous experiments remain to be performed, it might become possible to predict 
chemoresistance and to avoid ineffective drugs. The possibility of pretherapeutic 
discrimination between responders and non-responders will further stimulate the 
development of an individualised therapeutic strategy using a personalised combination of 
drugs (Dietel & Sers, 2006). A list of the genes and their response to therapy and drug 
resistance is presented in Table 5. 
 
 Gene Description Response to drugs 
G
e
n
e
s 
o
v
e
re
x
p
re
ss
e
d
 
HLA-
DQA1 
HLA class II histocompatibility antigen, DQ alpha 
1 chain 
Resistance to FA, C, 
CHB 
MAT2A Methionine adenosyltransferase 2 
Resistance to FA, C, 
CHB 
FMOD Fibromodulin 
Resistance to FA, C, 
CHB 
EGR1 Early growth response protein 1 
Positive effect to 
TPA 
CD69 Early lymphocyte activation antigen 
Positive effect to 
TPA 
PKC Protein kinase C Positive effect to TPA 
DPB2 DNA polymerase epsilon 
FA signature genes 
involved in DNA 
repair 
PCNA Proliferating cell nuclear antigen 
FA signature genes 
involved in DNA 
repair 
ADORA3 Adenosine A3 receptor FA, 2-CdA 
Gars-Airs-
Gar 
complex 
Phosphoribosylglycinamide 
synthetasephosphoribosylaminoimidazole 
synthetase-phosphoribosylglycinamide 
formyltransferase 
FA, 2-CdA 
mtAK3 Adenylate kinase 3 (mitochondrial) FA, 2-CdA 
NMN Myodenylate deaminase FA, 2-CdA 
CD26 Adenosine deaminase complexing protein FA, 2-CdA 
CD38 Cyclic ADP-ribose hydrolase FA, 2-CdA 
IL-18 Interleukin 18; interferon-gamma-inducing factor FA, 2-CdA 
IL-4 Interleukin-4; lymphocyte stimulatory factor 1 FA, 2-CdA 
RAD51 DNA repair protein Resistance to CHB 
BFL1 BCL2-related protein A1, BCL2A1 Positive effect to VPA 
C-MYC Transcription factor, puf, and kinase Positive effect to VPA 
DUSP2 Serine/threonine specific protein phosphatase Positive effect to VPA 
PEA15  Homolog of mouse MAT-1 oncogene Positive effect to VPA 
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STAT1 Signal transducer and activator of transcription 1 
Positive effect to 
Thalidomide 
Resistance to FA, C, 
CHB 
BLK B lymphoid tyrosine kinase 
Positive effect to 
Thalidomide 
Resistance to FA, C, 
CHB 
HSP27 Heat shock protein beta-2 
Positive effect to 
Thalidomide 
Resistance to FA, C, 
CHB 
ECH1 Enoyl CoA hydratase 1, peroxisomal 
Positive effect to 
Thalidomide 
Resistance to FA, C, 
CHB 
P21 CDKN1A, cyclin-dependent kinase inhibitor 1A 
Positive effect to 
Thalidomide 
Resistance to FA, C, 
CHB 
APRT Adenine phosphoribosyltransferase FA, 2-CdA 
IMPDH1 IMP dehydrogenase 1 FA, 2-CdA 
ADORA1 Adenosine A1 receptor FA, 2-CdA 
cAK1 Cytosolic adenylate kinase 1 FA, 2-CdA 
GRK6 G-prot-coupled receptor kinase 6 FA, 2-CdA 
CD73 5'-nucleotidase, ecto 
Bortezomib, 
Lumiliximab 
Positive effect to FA 
CD5 Lymphocyte antigen T1/Leu-1 
Positive effect to 
VPA 
BCL2 B cell lymphoma 2 associated oncogene 
Positive effect to 
VPA 
CD23 
FCER2, Fc fragment of IgE, low affinity II, receptor 
for CD23 
Positive effect to 
VPA 
PIM1 
Proto-oncogene serine/threonine-protein kinase 
PIM-1 
Positive effect to 
VPA 
C – cyclophosphamide, 2-CdA – cladribine, CHB – chlorambucil, FA – fludarabine,  
TPA – tetradecanoyl phorbol acetate, VPA – valproic acid 
Table 5. The influence of GEP on response to therapy or drug resistance (Edelmann et al., 
2008; Giannopoulos et al., 2009; Marinello et al., 2006; Plate et al., 2000; Proto-Siqueira et al., 
2008; Rosenwald et al., 2004; Segel et al., 2003; Stamatopoulos et al., 2009; Vallat et al., 2003).  
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3. Genotyping  
3.1 Introduction 
Owing to a greater availability of the human genome sequence, the focus of research has 
now been shifted to identifying sequence polymorphisms. It is of utmost importance to 
understand how biological functions may be affected by these variations and be associated 
with heritable phenotypes. 
A single nucleotide polymorphism (SNP) array is a type of DNA microarray that is used to 
detect polymorphisms within a population.  SNPs are the most frequent type of variation in 
the genome. It is estimated that about 10 million SNPs have been identified in humans, an 
average of one SNP every 400–1000 base pairs (Botstein & Risch, 2003). Currently, about 5.6 
million have been typed (dbSNP Build ID: 126), about half of which are estimated to have a 
minor allele frequency over 10% (Kruglyak & Nickerson, 2001). As SNPs are highly conserved 
throughout evolution and within a population, a map of SNPs serves as an excellent genotypic 
marker for research. SNPs from the whole genome form a genetic fingerprint. Although SNPs 
are spaced randomly throughout the genome and could therefore lie in coding sequences, only 
a small fraction has functional significance (i.e. are non-silent), such as those found in the 
transcribed or regulatory regions of genes (Mohr et al., 2002). SNPs on a small chromosomal 
segment tend to be transmitted as a block, forming a haplotype. This correlation between 
alleles at nearby sites is known as linkage disequilibrium (LD) and enables genotypes at a 
large number of SNP loci to be predicted from known genotypes at a smaller number of 
representative SNPs, called tag SNPs or haplotype tag SNPs (Gabriel et al., 2002; Dutt & 
Beroukhim, 2007). This reduction in the complexity of genetic variation among individuals 
enables an overall genotype to be determined much more efficiently and economically; 
roughly 500,000 tag SNPs are sufficient to genotype an individual with European ancestry 
(Dutt & Beroukhim, 2007; Nicolas et al., 2006). 
The mechanisms of an SNP array and the DNA microarray are identical; the convergence of 
DNA hybridization, fluorescence microscopy and solid surface DNA capture. In order to 
study the genetic vulnerability of a germline to complex diseases, oligonucleotide arrays 
have been developed to interrogate such large numbers of SNP markers in multiple 
databases (Dutt & Beroukhim, 2007; Gunderson et al., 2005).  
3.2 Genome-wide association studies 
CLL and other B-cell lymphoproliferative disorders (LPDs) show clear evidence of familial 
aggregation, but the inherited basis is still largely unknown. To identify a susceptibility gene 
for CLL, Sellick et al., (2005) conducted a genome-wide linkage analysis of 115 families, using a 
high-density SNP array (GeneChip Mapping 10Kv1 Xba, Affymetrix) containing 11,560 
markers. Multipoint linkage analyses were undertaken using both nonparametric (model-free) 
and parametric (model-based) methods. It confirmed that high LD between SNP markers 
could lead to inflated nonparametric linkage (NLP) and LOD scores (Dawn Tare & Barrett, 
2005). After the high-LD SNPs were removed, a maximum NPL of 3.14 (p<0.0008) on 
chromosome (11)(p11) was obtained. The highest multipoint heterogeneity LOD (HLOD) score 
under both dominant (HLOD 1.95) and recessive (HLOD 2.78) models was yielded by the 
same genomic position. Moreover, four other chromosomal positions (5)(q22-23), (6)(p22), 
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(10)(q25) and (14)(q32) displayed HLOD scores >1.15 (p<0.01). None of those regions 
coincided with areas of common chromosomal abnormalities frequently observed for CLL. 
These results support an inherited predisposition to CLL and related B-cell LPDs. 
Pfeifer at al., (2007) explored high-density 10k and 50k Affymetrix SNP arrays to assess 
genetic aberrations in the tumour B-cells of patients with CLL. Among the prognostically 
important aberrations, del(13)(q14) was present in 51%, trisomy 12 (+12) in 13%, del(11)(q22) 
in 13% and del(17)(p13) in about 6% of cases. A prominent clustering of breakpoints on both 
sides of the genes MIRN15A/MIRN16-1 indicated the presence of recombination hot spots in 
the 13q14 region. Patients with a mono-allelic del(13)(q14) had slower lymphocyte growth 
kinetics than patients with bi-allelic deletions. In four CLL cases with unmutated HV genes, 
a common minimal 3.5-Mb gain of 2p16 spanning the REL and BCL11A oncogenes was 
identified, implicating these genes in the pathogenesis of CLL. 
New risk variants for CLL were identified by Crowther-Swanepoel et al., (2010). A genome-
wide association (GWA) study of 299,983 tagging SNPs (by means of HumanCNV370-Duo 
BeadChips, Illumina) was conducted with validation in four additional series totalling 2,503 
cases and 5,789 controls. In 2008, the authors reported the results of a GWA study of CLL 
based on an analysis of 299,983 tagging SNPs in 505 cases and 1, 438 controls and through 
fast track analysis of SNPs, identified risk loci at 2q13, 2q37.1, 6p25.3, 11q24.1, 15q23 and 
19q13.32 (Di Bernardo et al., 2008). The authors identified 4 new risk loci for CLL at 8q24.21 
(rs2456449, TCF4), 2q37.3 (rs757978, FARP2), 15q21.3 (rs7169431, NEDD4, RFX7) and 16q24.1 
(rs305061, IRF8). The evidence for risk was found for two more loci: 15q25.2 (rs783540, 
CPEB1) and 18q21.1 (rs1036935, CXXC1, MBD1). TCF4 binds to an enhancer for MYC, 
providing a mechanistic basis for this 8q24.21 association. It had also been shown that 
variation in IRF4 influences CLL risk. There is a possibility that the effect of the other 
8q24.21 cancer risk loci is by MYC, which is a direct target of IRF4 in activated B-cells and 
this observation needs further study.  
FARP2 is a gene connected with signalling downstream of G protein-coupled receptors. 
rs757978 is involved in the substitution of threonine for isoleucine at amino acid 260 (T260I), 
whereas rs305061 maps within a 30-kb region of LD at 16q24.1 locus and localises 19kb 
telomeric to IRF8, which regulates  and -interferon response. There is still no evidence for 
a direct role of NEDD4 in CLL, but it is a credible candidate gene because it has a role in 
regulating viral latency and pathogenesis of EBV. Particularly, NEDD4 regulates EBV-
LMP2A, which mimics signalling induced by the B-cell receptor, altering B-cell 
development. CPEB1 plays a role in regulating cyclin B1 during embryonic cell division and 
differentiation. CXXC1 and MBD1 are involved in gene regulation. MBD1 expression in 
EBV-transformed lymphocytes correlated with risk genotype. Although MBD1 has no 
documented role in CLL, it can affect CLL development through translational control of 
MYC. No connection between 17p deletion status and genotype was observed. Although 
there was evidence that the rs305061 risk genotype was associated with worse overall 
survival, IGHV-mutation status was highly correlated with rs305061, but risk genotype 
correlating with unmutated-CLL (Crowther-Swanepoel et al., 2010; Di Bernardo et al., 2008).        
To identify genetic variants associated with outcome of CLL, Sellick et al., (2008) genotyped 
977 non-synonymous SNPs (nsSNPs) in 755 genes relevant to cancer biology in 425 patients 
participating in a trial comparing the efficacies of FA and CHB ± C in first-line treatment. A 
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total of 78 SNPs (51 dominantly acting and 27 recessively acting) were associated with 
progression-free survival (PFS), nine of them also affecting overall survival (OS) at the 5% 
level. These included SNPs mapping to the immunoregulatory genes IL16 P434S, IL19 S213F, 
LILRA4 P27L, KLRC4 S29I and CD5 V471A, as well as the DNA response genes POLB P242R 
and TOPBP1 S730L, which were all independently prognostic of IGHV mutational status. A 
total of five SNPs associated with PFS were common to patients treated with CHB or FA 
(DST L22S, LILRA4 P27L, SEC23B H489Q, XRCC2 R188H and ZAK S531L); three SNPs were 
common to patients treated with either CHB or FA with C (APBB3 C236R, ENPPS I171V, 
and C21orf57 S2L); and four were common to patients treated with either FA alone or FA 
with C (DDX27 G206V, DPYD S534N, WNT16 G72R and DHX16 D566G). The variants have 
proved to be invaluable prognostic markers of patient outcome (Table 6).  
 
Gene Description Chemotherapy 
Response 
to 
treatment 
DST  L22S Dystonin 
CHB or FA 
PFS 
LILRA4  
P27L 
Leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 4 
PFS 
SEC23B  
H489Q 
SEC23-related protein B PFS, OS 
XRCC2  
R188H 
DNA repair protein XRCC2; RAD51-like PFS 
ZAK  S531L 
MLK-like mitogen-activated protein triple 
kinase 
PFS 
APBB3  
C236R 
Amyloid beta A4 precursor protein-binding 
family B member 3 
CHB or FC 
PFS 
ENPPS  
I171V 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 1 
PFS 
C21orf57  
S2L 
Chromosome 21 open reading frame 57 PFS 
DDX27  
G206V 
DEAD box protein 27 
FA or FC 
PFS 
DPYD  
S534N 
Dihydropyrimidine dehydrogenase PFS 
WNT16  
G72R 
Wingless-type MMTV integration site family, 
member 16 
PFS 
DHX16  
D566G 
DEAH (Asp-Glu-Ala-His) box polypeptide 16 PFS 
FA – fludarabine, FC – fludarabine with cyclophosphamide, CHB – chlorambucil;  
PFS – progression-free survival, OS – overall survival 
Table 6. Relationship between SNPs and drug response (Sellic et al., 2008) 
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3.3 Copy number variation analyses 
Gunnarsson et al., (2008) compared platform dynamics, an in-depth analysis of copy-
number alterations (CNAs) using four high-resolution microarray platforms: BAC arrays 
(32K), oligonucleotide arrays (185K, Agilent) and two SNP arrays (250K, Affymetrix and 
317K, Illumina). Ten CLL samples were analysed. The evaluation of baseline variation and 
copy-number ratio response showed that the Agilent platform performed best and 
confirmed the robustness of BAC arrays. These platforms demonstrated more platform-
specific CNAs. The SNP arrays showed more technical diversity, although the high density 
of elements compensated for this. Affymetrix detected more CNAs than Illumina, but the 
latter showed a lower noise level and a higher detection rate in the LOH analysis. 
Application of high-resolution microarrays will enhance the possibility of detecting new 
recurrent microevents in CLL leading to identification of new important subgroups, refining 
the prognostic hierarchy established by FISH. The whole-genome screening with SNP arrays 
(Affymetrix GeneChip Mapping 250K Nsp1) was conducted and a high frequency of known 
recurrent alterations in 203 newly diagnosed CLL patients was revealed (Gunnarsson et al., 
2010). Moreover, the genome-wide analysis allowed detection of a novel combination of 
gain of 2p and del(11q), and additional large and small CNAs, which are important for the 
evaluation of overall complexity in CLL patients. The authors identified genomic 
complexity as a poor prognostic marker in the survival analysis. However, they noted that 
this characteristic was strongly linked to established poor-risk molecular markers. The small 
alterations were mostly non-overlapping. It seems unlikely that there are unknown 
recurrent CNAs > 200 kbp involved in the CLL pathophysiology detectable in this setting 
(Gunnarsson et al., 2010). Similar results have been presented by Kujawski et al., (2008), who 
reported a correlation between genomic complexity and a significantly shorter time to first 
and second treatment and presented the number of CNAs as an independent prognosis 
factor. 
The discovery of microRNA and its biological functions is a significant step towards the 
understanding of the molecular bases of human physiology and pathology. MicroRNAs 
constitute a class of short, non-coding RNA molecules involved in the regulation of a 
number of important biological process including cell proliferation, differentiation and 
apoptosis by down-regulation of gene expression during the translation phase. On the basis 
of these findings, CLL is a genetic disease in which the main alterations occur in microRNAs 
(miRNAs). Down-regulation of MIR15A and MIR16 as a part of del(13)(q14) has been 
suggested as good prognostic factors. Both miRNAs negatively regulate BCL2 at a post-
transcriptional level. In CLL cases with unmutated IGHV or high level of expression ZAP70 
the overexpression of TCL1 was observed. This is due to low-level expression of MIR29 and 
MIR181, which directly targets this oncogene. The overexpression of TCL1 is correlated with 
del(11)(q22) and with the aggressive CLL. These miRNAs might be used to target BCL2 or 
TCL1 for therapy of the disease (Calin et al., 2007; Cimmino et al., 2005). 
Ouillette et al., (2008) analysed 171 CLL cases for LOH and subchromosomal copy loss on 
chromosome 13 in DNA from FACS-sorted CD19+ cells by means of the Affymetrix XbaI 50k 
SNP array platform. Detailed analysis suggests the existence of distinct subtypes. 
Categorisation is based on del(13)(q14) lesions with Rb loss as type II [40% of del(13)(q14) 
cases] and consequently without such a loss as type I [60% of del(13)(q14) cases]. Rb is a 
decisive regulator of cell cycle progression and genomic stability. The loss of one or two alleles 
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could differentially affect the biology of CLL cases Hernando et al., 2004. In the type I 198 
genes were analysed. In this group reduced expression of FLJ11712, KCNRG, RFP2, RFP2OS 
and DLEU1 was identified. Many other genes have emerged as candidate differentially 
expressed genes by means of qPCR: LATS2, DFNA5, PHLPP, LPIN1, SERPINE2, ARHGAP20, 
CYTB5, SLA2, and AQP3. LATS2 RNA levels were lower in CLL cases with del(13)(q14) type I 
as opposed to type II cases or all other CLL cases without del(13)(q14). LATS2 is involved in 
cell cycle progression control. It is possible that Rb and LATS2 may be regulators [in non-
del(13)(q14) cases] in different processes of CLL subsets (Ouillette et al., 2008). Further 
subdivision of del(13)(q14) type I cases into type Ia and type Ib is suggested by the occurrence 
of deletions that appear of relatively uniform length [del(13)(q14) type Ia] and that displays 
centromeric breaks within the vicinity of the MIR15A/MIR16 cluster. Bi-allelic del(13)(q14) type 
Ia lesions were associated with significant reductions in MIR15A/MIR16 expression levels. As 
opposed to Calin et al. (2007), this observation reveals that BCL2 levels were not correlated 
with MIR15A/MIR16 levels. In important recent discovery is that about 50% of all CLL cases 
with del(13)(q14) do not express the PHLPP gene. PHLPP dephosphorylates activated AKT 
and low or absent PHLPP expression may allow for sustained AKT signalling after proper cell 
surface stimuli (Ouilette et al., 2008).  
Multiple, discrete, genomic alterations in the 13q region, including MIR15A/MIR16, Rb 
and others were also observed by Grubor et al., (2009). It might suggest greater 
complexity of lesions in the 13q region than already known. Moreover, they focused on 
intraclonal heterogeneity within CLL patients and they searched for genomic differences 
between CD38+ and CD38- populations in the same patient. The study was conducted by 
means of a high-resolution CGH technique called representational oligonucleotide 
microarray analysis (ROMA). This method is very sensitive to examining the clonal 
heterogeneity of CLL within the same patient from mixed subpopulations. Copy number 
differences, in separated CD38+ and CD38- fractions, were detected in 3 of 4 samples at 
various loci throughout the genome, some of clinical relevance (ie. ATM and TP53). With 
the exception of the del(6)(q21), reported major cytogenetic imbalances have been 
observed previously. The majority of lesions (315/419) were deletions and not 
amplifications, which is typical of CLL. Two novel regions were observed: del(8)(p21.2-
p12) and del(2)(q37.1), including genes TRIM35 and SP100/110/140, respectively. The 
apparent on-going evolution of CLL clones in a patient may improve the understanding 
of the disease and the ability to identify patients at risk. The above-demonstrated 
capabilities offer opportunities for patient treatment individualisation and the 
identification of new therapeutic agents.   
Lehmann et al., (2008) performed molecular allelokaryotyping on 56 samples of early stage 
CLL using the 50k XbaI GeneChip from Affymetrix (50,000 SNP probes). Excluding the four 
common abnormalities [+12, del(17)(p13), del(11)(q22) and del(13)(q14)], SNP-chip analysis 
identified a total of 45 copy number changes in 25 CLL samples (45%). Four samples had 
del(6)(q21) that involved AIM1. UPD was detected in four samples, two of them involved 
the whole of chromosome 13, resulting in homozygous deletion of MIR15A/MIR16-1. The 
data suggests that genetic abnormalities including gain, loss and UPD of genetic materials 
frequently occur at an early stage of CLL. In addition to well-documented common genetic 
abnormalities, deletions of 5q, 6q and Xp were observed to be frequent in early-stage CLL. 
AIM1 was examined as a target of this deletion. In the study, expression levels of ZAP70 and 
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the mutational status of IGHV were analysed. It was demonstrated for the first time that 
ZAP70 expression was correlated with del(11)(q22) in early-stage CLL. It was also observed 
that non-hypermutation of IGHV was correlated with +12, del(11)(q22) and del(13)(q14) in 
early-stage CLL. 
4. Conclusion 
Microarray technology provides comprehensive data on the expression patterns of 
thousands of genes in parallel, which positions this method in the centre of optimisation of 
diagnosis and the classification of leukemias. GEP may lead to the detection of new 
biologically defined and clinically relevant subtypes of chronic lymphocytic leukemia as a 
basis for specific therapeutic decision. If such testing is to be used as a routine method for 
diagnostic purposes in parallel with current standard methods, it is crucial to include GEP 
in future routine diagnostic applications and in clinical trials.  With promising initial results, 
genome-wide association studies using SNPs are becoming increasingly well established as 
tools for discovering disease genes. SNP array is an important application in determining 
disease susceptibility, and consequently in pharmacogenomics, by measuring the specific 
effectiveness of a form of drug therapy for the patient. As each individual has many SNPs 
that together create a unique DNA sequence. SNPs may be performed to map disease loci, 
and hence determine individual-specific disease susceptibility genes. As a result, drugs can 
be personally designed to act efficiently on a group of individuals who share a common 
allele, or even a single individual. 
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